Chengdu Olymvax Biopharmaceuticals (SH:688319) 智通财经网·2025-11-25 23:27Company Overview - 欧林生物 is a global, innovation-driven biopharmaceutical company focused on the research, development, production, and commercialization of innovative vaccines, particularly in the areas of "superbug vaccines" and "adult vaccines" [2][3] - Unlike many biotechnology companies that have yet to generate revenue, 欧林生物 has a mature commercialization platform with three products already commercialized: Tetanus Toxoid Vaccine, Hib Conjugate Vaccine, and AC Conjugate Vaccine [2] Market Position - The company's Tetanus Toxoid Vaccine holds a leading market position in China, with a market share exceeding 80% from 2022 to 2024 [2] - 欧林生物 possesses the most comprehensive pipeline targeting "superbugs" globally, addressing significant public health challenges due to antibiotic resistance [2][3] Product Pipeline - The company is developing a 1.1 class innovative superbug candidate vaccine targeting five pathogens, including: - Recombinant Staphylococcus aureus Vaccine (rFSAV) - Oral Recombinant Helicobacter pylori Vaccine (rHPV) - Recombinant Pseudomonas aeruginosa Vaccine (rFPAV) - Recombinant Acinetobacter baumannii Protein Vaccine (rABV) - Group A Streptococcus Vaccine (GAS Vaccine) [2] Financial Performance - Revenue for 欧林生物 is projected as follows: - 2022: approximately 547 million RMB - 2023: approximately 494 million RMB - 2024: approximately 586 million RMB - 2024 (first half): approximately 225 million RMB - 2025 (first half): approximately 305 million RMB [4][6] - Profit figures are as follows: - 2022: approximately 26.58 million RMB - 2023: approximately 11.44 million RMB - 2024: approximately 15.72 million RMB - 2024 (first half): approximately -30.72 million RMB - 2025 (first half): approximately 13.23 million RMB [5][6] Industry Overview - The global vaccine market (excluding COVID-19 vaccines) is expected to grow from 52.9 billion USD in 2019 to 73.8 billion USD by 2024, with a CAGR of 6.9% [8] - The Chinese vaccine market (excluding COVID-19 vaccines) is projected to grow from 42.5 billion RMB in 2019 to 102 billion RMB by 2024, with a CAGR of 19.1% [8] - The Tetanus vaccine market in China is experiencing rapid growth, expected to increase from 200 million RMB in 2019 to 800 million RMB by 2024, with a CAGR of 40.2% [10]